Kalaris Therapeutics Inc
KLRS
查看详细走势图
8.340USD
-0.010-0.12%
收盘 02/06, 16:00（美东）报价延迟15分钟
155.98M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.12%
5天
-6.08%
1月
-4.79%
6月
+207.75%
今年开始到现在
-1.18%
1年
-17.01%
查看详细走势图
TradingKey Kalaris Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Kalaris Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业偏弱水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名165/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价18.60。中期看，股价处于上升通道。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kalaris Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Kalaris Therapeutics Inc亮点
亮点风险
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
估值高估
公司最新PE估值-0.04，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值112.75K
分析师目标
根据
6
位分析师
买入
评级
18.600
目标均价
+110.65%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kalaris Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kalaris Therapeutics Inc简介
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
公司代码KLRS
公司Kalaris Therapeutics Inc
CEOOxtoby (Andrew)
网址https://kalaristx.com/
相关品种
